What does HEW PHARMA do?

HEW PHARMA is a wholesaler in Kalmthout. Private Limited, started on 20 September 2017, 1 establishment.

What is the address of HEW PHARMA?

The registered office of HEW PHARMA is located at Heiken (Ab) 5, 2920 Kalmthout.

Is HEW PHARMA still active?

Yes. According to the CBE (29 October 2026) HEW PHARMA is active, legal situation “Normale toestand”, started on 20 September 2017.

Is HEW PHARMA registered on Peppol?

Yes, HEW PHARMA is registered on the Peppol network with ID 0208:0681590393.

What is the enterprise number of HEW PHARMA?

The enterprise number of HEW PHARMA is BE0681590393.

When was HEW PHARMA founded?

HEW PHARMA was founded on 20 September 2017.

Who are the directors of HEW PHARMA?

According to the 2025 annual accounts, the directors of HEW PHARMA are: Peter De Sutter, WEBINVEST BV, Ann Denert.

Is HEW PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 September 2017; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did HEW PHARMA make in 2025?

HEW PHARMA posted a profit after taxes of € 30,396 in financial year 2025.

What is the revenue of HEW PHARMA?

As a small company, HEW PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 129,937.

How much does an employee at HEW PHARMA earn?

The average wage cost per full-time employee at HEW PHARMA was € 61,400 in 2022: staff costs of € 110,550 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

HEW PHARMA (Private Limited) - Kalmthout - BE0681590393

Dossier HEW PHARMA, printed on 29 October 2026 from databakkes.be/en/0681590393/hew-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

HEW PHARMA from Kalmthout, company number BE0681590393, closed financial year 2025 with a result of € 30,396 after tax. For that financial year HEW PHARMA recorded a gross margin of € 129,937 and equity of € 279,177. Compared with financial year 2024, the result moved from € -87,290 to € 30,396. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Growing

€ 279,177

▲ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 30,396

▲ still € 87,290 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 487,751

▲ 14% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 260,627.

People and assets in 2025

Wage cost

€ 92,863

▲ 34% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,159

▲ € 2,836 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 160,814

▲ 1% vs 2024

€ 70,814 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 466,712

▼ 7% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 62,974

▲ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 204,231 Gross margin 2022: € 204,231 First fiscal year in the series	€ 166,183 Gross margin 2023: € 166,183 ▼ 19% vs 2022 (€ 204,231) Unfavourable step	€ 29,521 Gross margin 2024: € 29,521 ▼ 82% vs 2023 (€ 166,183) Unfavourable step	€ 129,937 Gross margin 2025: € 129,937 ▲ € 100,416 vs 2024 (€ 29,521) Favourable step	▲ € 100,416
Profit after taxes	€ 69,617 Profit after taxes 2022: € 69,617 First fiscal year in the series	€ 62,167 Profit after taxes 2023: € 62,167 ▼ 11% vs 2022 (€ 69,617) Unfavourable step	€ -87,290 Profit after taxes 2024: € -87,290 ▼ € 149,457 vs 2023 (€ 62,167) Unfavourable step	€ 30,396 Profit after taxes 2025: € 30,396 ▲ € 117,686 vs 2024 (€ -87,290) Favourable step	▲ € 117,686
Equity	€ 273,905 Equity 2022: € 273,905 First fiscal year in the series	€ 336,072 Equity 2023: € 336,072 ▲ 23% vs 2022 (€ 273,905) Favourable step	€ 248,782 Equity 2024: € 248,782 ▼ 26% vs 2023 (€ 336,072) Unfavourable step	€ 279,177 Equity 2025: € 279,177 ▲ 12% vs 2024 (€ 248,782) Favourable step	▲ 12%
Total debts	€ 441,132 Total debts 2022: € 441,132 First fiscal year in the series	€ 677,406 Total debts 2023: € 677,406 ▲ 54% vs 2022 (€ 441,132) Unfavourable step	€ 740,455 Total debts 2024: € 740,455 ▲ 9% vs 2023 (€ 677,406) Unfavourable step	€ 726,882 Total debts 2025: € 726,882 ▼ 2% vs 2024 (€ 740,455) Favourable step	▼ 2%
Cash	€ 405,488 Cash 2022: € 405,488 First fiscal year in the series	€ 428,965 Cash 2023: € 428,965 ▲ 6% vs 2022 (€ 405,488) Favourable step	€ 429,384 Cash 2024: € 429,384 Unchanged (€ 428,965) Favourable step	€ 487,751 Cash 2025: € 487,751 ▲ 14% vs 2024 (€ 429,384) Favourable step	▲ 14%
Retained profit	€ 255,355 Retained profit 2022: € 255,355 First fiscal year in the series	€ 317,522 Retained profit 2023: € 317,522 ▲ 24% vs 2022 (€ 255,355) Favourable step	€ 230,232 Retained profit 2024: € 230,232 ▼ 27% vs 2023 (€ 317,522) Unfavourable step	€ 260,627 Retained profit 2025: € 260,627 ▲ 13% vs 2024 (€ 230,232) Favourable step	▲ 13%
Bank debt	€ 172,830 Bank debt 2022: € 172,830 First fiscal year in the series	€ 160,814 Bank debt 2023: € 160,814 ▼ 7% vs 2022 (€ 172,830) Favourable step	€ 159,539 Bank debt 2024: € 159,539 ▼ 1% vs 2023 (€ 160,814) Favourable step	€ 160,814 Bank debt 2025: € 160,814 ▲ 1% vs 2024 (€ 159,539) Unfavourable step	▲ 1%
Balance sheet total	€ 715,037 Balance sheet total 2022: € 715,037 First fiscal year in the series	€ 1,013,478 Balance sheet total 2023: € 1,013,478 ▲ 42% vs 2022 (€ 715,037) Unchanged	€ 989,236 Balance sheet total 2024: € 989,236 ▼ 2% vs 2023 (€ 1,013,478) Unchanged	€ 1,006,059 Balance sheet total 2025: € 1,006,059 ▲ 2% vs 2024 (€ 989,236) Unchanged	▲ 2%
Employees (FTE)	1.8 Employees (FTE) 2022: 1.8 First fiscal year in the series	-	-	-

Key figures of HEW PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HEW PHARMA?

What happened at HEW PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: profit of € 30,396. filed late Source: NBB ↗
2022 Peter De Sutter became a director. NBB
Sep 20, 2017 New establishment in Kalmthout. KBO
Sep 20, 2017 Start of the company according to the CBE. KBO
2017 WEBINVEST BV became a director. NBB
2017 Ann Denert became a director. NBB

In short

From € 69,617 profit in 2022 to € 30,396 profit in 2025.

Paid € 32,034 in corporate taxes since 2022.

Best year ever: 2022, with € 69,617 profit.

On average € 113,500 of value added per employee in 2022.

Original PDFs at the National Bank ↗

Management

WEBINVEST 60%

FAGRON 20%

The stake of WEBINVEST, FAGRON comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

HEW PHARMA

Behind HEW PHARMA are Peter De Sutter, WEBINVEST BV and Ann Denert. The shares are held by WEBINVEST (60%) and FAGRON (20%).

Directors

According to the 2025 annual accounts

Peter De Sutter

Director

Also active at: Conforma, BIO MINERALS, JoLea Consult

since 2022

WEBINVEST BV

Director · represented by Rombouts Gunther

Also active at: BelCoPhar

since 2017

Ann Denert

Director

Also active at: BelCoPhar

since 2017

Shareholders

WEBINVEST

60%

FAGRON

20%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Heiken (Ab) 5

2920 Kalmthout

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

HEW AUTOMATION

€ 1 million gross margin · 2024

BelCoPhar same network

€ 56,874 gross margin · 2025

WEBINVEST same network

€ 124,544 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0681.590.393

VAT number

BE 0681.590.393

Registered office

Heiken (Ab) 5, 2920 Kalmthout

Names & denominations

HEW PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

20 September 2017

Peppol

Active · Active since 2 Jan 2026

Activities · NACE

Groothandel in parfumerieën en cosmetica

Vervaardiging van geneesmiddelen

Activiteiten op het gebied van voeding

Detailhandel in dames-, heren-, baby- en kinderboven- en onderkleding en kledingaccessoires (algemeen assortiment)

Groothandel in overig textiel

Vervaardiging van farmaceutische grondstoffen

Overige menselijke gezondheidszorg, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

HEW PHARMA

Financials

What happened to HEW PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions